Visualizing Health Policy: Medicare and End-of-Life Care
This Visualizing Health Policy infographic, produced in partnership with the Journal of the American Medical Association (JAMA), provides a snapshot of Medicare and end-of-life care
View the Latest: Federal Budget
Filter
-
-
The Status of Funding for Zika: The President’s Request, Congressional Proposals, & Final Funding
Issue BriefThis issue brief provides a landscape of the status of U.S. funding for Zika, a mosquito-transmitted infection that in pregnant women can cause microcephaly as well as other serious birth defects. The brief compares the Congressionally approved Zika funding levels, which provides $1.1 billion to the Zika response, to the President’s February 22nd request, the House and Senate bills that passed each chamber in May, and a Conference Agreement that had been approved by the House in June, but was blocked in the Senate and opposed by the Administration.
-
Web Event: Rx Drugs and the U.S. Health System – A Conversation about Election-Cycle Proposals for Lowering Costs
Event Date:EventOn Wednesday, October 5, from noon to 1 p.m. ET, the Kaiser Family Foundation will host a web conversation to discuss proposals for controlling prescription drug costs, examine pros and cons of the ideas, and assess the likelihood that the plans will be enacted.
-
Medicare Part D Spending on the EpiPen Increased More than 1000 Percent from 2007 to 2014
News ReleaseAs policymakers in Washington scrutinize the rising cost of the EpiPen auto-injector, a new analysis from the Kaiser Family Foundation shows that Medicare Part D spending for the potentially life-saving device increased by more than 1000 percent between 2007, the year after the Part D drug benefit took effect, and 2014, the most recent year…
-
How Much Has Medicare Spent on the EpiPen Since 2007?
Issue BriefThis data note examines the effects of rising EpiPen prices on Medicare and beneficiaries. We analyze EpiPen spending, in the aggregate and per user, in Medicare Part D between 2007 (the year after the Part D drug benefit took effect, and the year Mylan acquired the product) and 2014 (the most recent year of data available).
-
Web Event: Rx Drugs and the U.S. Health System: A Conversation about Medicare Prescription Drug Costs
Event Date:EventOn Wednesday, September 7, from noon to 1 p.m. ET, the Kaiser Family Foundation hosted a web conversation to discuss trends in Medicare prescription drug spending, as well as proposals to reduce costs and forecasts of what beneficiaries can expect in coming years.
-
The Status of Funding for Zika: Comparing the President’s Request and Congressional Proposals
News ReleaseZika, a mosquito-transmitted infection that in pregnant women can cause microcephaly as well as other serious birth defects, has recently become a global challenge, and with the first cases of local transmission now reported in the U.S., a domestic one as well. No new funding for Zika has yet been appropriated by Congress.
-
Key Implementers of U.S. Global Health Efforts
Issue BriefThis brief provides an overview of the implementing organizations that received U.S. global health funding from the U.S. Agency for International Development (USAID) in FY 2015.
-
Turning Medicare Into a Premium Support System: Frequently Asked Questions
Issue BriefPremium support is a general term used to describe an approach to reform Medicare that aims to reduce the growth in Medicare spending. These FAQs raise and discuss basic questions about the possible effects of a premium support system for Medicare beneficiaries, the federal budget, health care providers, and private health plans.
-
Questions and Answers about Turning Medicare into a Premium Support System
News ReleaseWith its inclusion in the House GOP health plan released last month, the idea of converting Medicare into a premium support system once again features prominently in Capitol Hill policy discussions about the future of Medicare, the federal health insurance program that covers 57 million seniors and people with disabilities.